Posts tagged license agreement
HCW starts XOMA at buy

H.C. Wainwright initiated coverage of XOMA (NASDAQ:XOMA) with a “buy” rating and $15 price target. The stock closed at $6.86 June 12th.

Read More
IntelGenx, RedHill license Rizaport in Korea

IntelGenx (OTCQX:IGXT; TSX-V:IGX) and RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) have signed an exclusive license agreement with Pharmatronic for the commercialization of Rizaport in South Korea.

Read More
Ocular, Regeneron in wet AMD collaboration

Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular endothelial growth factor (VEGF) trap, aflibercept, for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases.

Regeneron’s aflibercept has been approved by the FDA for certain indications under the brand name, EYLEA.

Read More
EyeGate gets additional milestone payment from Valeant

EyeGate Pharmaceuticals (NASDAQ:EYEG) has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX:VRX).

EyeGate previously granted Valeant exclusive, worldwide commercial and manufacturing rights to its EyeGate II Delivery System and EGP-437 combination product in the field of uveitis, as well as a right of last negotiation to license the product for other indications.

Read More